HDL cholesterol and residual risk of first cardiovascular events after treatment with potent statin therapy: an analysis from the JUPITER trial : The Lancet

• Verify Information

  Please verify your information below and fill out all required fields marked in red.

• Contact Name *
• Specialty *
• Focus *
• Mobile Phone *
• Email *

Send Information